EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma

View source ↗

Summary

The European Medicines Agency authorised Cometriq (cabozantinib) for thyroid neoplasms, with Ipsen Pharma as the marketing authorisation holder, and it carries …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Thyroid Neoplasms

Drugs mentioned

• COMETRIQ (CABOZANTINIB)

Snippet

Status: Authorised. Therapeutic area: Thyroid Neoplasms. MAH: Ipsen Pharma. Decision date: 15/01/2026. Orphan medicine